CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported Current Deferred Revenue of $15.3 million for Q1 2026, up 407.91% on a YoY basis from $3.0 million in Q1 2025, and down 2.71% sequentially from $15.8 million in Q4 2025.
CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 10 years of Current Deferred Revenue data on file, last reported at $15.3 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 407.91% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (up 407.91% YoY), and the FY2025 full-year result was $15.8 million, up 310.17% from the prior year.
- Current Deferred Revenue slipped to $15.3 million in Q1 2026, from $15.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $15.8 million in Q4 2025 to a low of $1.3 million in Q3 2025.
- A 4-year average of $6.4 million and a median of $4.1 million in 2024 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue plunged 71.11% in 2025 and jumped 407.91% in 2026, its largest moves.
- Tracing CRSP's Current Deferred Revenue over 4 years: stood at $12.3 million in 2023, then sank by 68.74% to $3.8 million in 2024, then surged by 310.17% to $15.8 million in 2025, then retreated by 2.71% to $15.3 million in 2026.
- Business Quant data shows CRSP's Current Deferred Revenue at $15.3 million in Q1 2026, $15.8 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.34 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 3.02 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 4.07 Mn |
| Dec 31, 2023 | 12.30 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 1.56 Mn |
| Jun 30, 2021 | 2.07 Mn |
| Mar 31, 2021 | 1.80 Mn |
| Dec 31, 2020 | 12.20 Mn |
| Sep 30, 2020 | 610,000.00 |
| Jun 30, 2020 | 759,000.00 |
| Mar 31, 2020 | 803,000.00 |
| Dec 31, 2019 | 960,000.00 |